Department of Rheumatology, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
Molecular Biology Research Center & Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, China.
Appl Microbiol Biotechnol. 2020 Jan;104(2):575-587. doi: 10.1007/s00253-019-10257-8. Epub 2019 Dec 12.
Autophagy is a highly conserved catabolic process and participates in a variety of cellular biological activities. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway, as a critical regulator of autophagy, is involved in the initiation and promotion of a series of pathological disorders including various tumors. Autophagy also participates in regulating the balance between the tumor and the tumor microenvironment. Natural products have been considered a treasure of new drug discoveries and are of great value to medicine. Mounting evidence has suggested that numerous natural products are targeting PI3K/AKT/mTOR-mediated autophagy, thereby suppressing tumor growth. Furthermore, autophagy plays a "double-edged sword" role in different tumors. Targeting PI3K/AKT/mTOR-mediated autophagy is an important therapeutic strategy for a variety of tumors, and plays important roles in enhancing the chemosensitivity of tumor cells and avoiding drug resistance. Therefore, we summarized the roles of PI3K/AKT/mTOR-mediated autophagy in tumorigenesis, progression, and drug resistance of tumors, which may be utilized to design preferably therapeutic strategies for various tumors.
自噬是一种高度保守的分解代谢过程,参与多种细胞生物学活动。磷酸肌醇 3-激酶(PI3K)/蛋白激酶 B(AKT)/雷帕霉素靶蛋白(mTOR)通路作为自噬的关键调节因子,参与了包括各种肿瘤在内的一系列病理紊乱的起始和促进。自噬还参与调节肿瘤与肿瘤微环境之间的平衡。天然产物一直被认为是新药发现的宝库,对医学具有重要价值。越来越多的证据表明,许多天然产物靶向 PI3K/AKT/mTOR 介导的自噬,从而抑制肿瘤生长。此外,自噬在不同肿瘤中扮演着“双刃剑”的角色。靶向 PI3K/AKT/mTOR 介导的自噬是多种肿瘤的重要治疗策略,在增强肿瘤细胞的化疗敏感性和避免耐药性方面发挥着重要作用。因此,我们总结了 PI3K/AKT/mTOR 介导的自噬在肿瘤发生、进展和耐药性中的作用,这可能有助于设计针对各种肿瘤的更佳治疗策略。
Appl Microbiol Biotechnol. 2019-12-12
Anticancer Agents Med Chem. 2013-9
Biomedicines. 2025-8-2
Cancer Cell Int. 2025-8-18
MedComm (2020). 2025-7-30